Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study.

Piero Ruggenenti Federico RaimondiMonica CortinovisLuca LoriniSilvia SalaLuca Novelli Federico RaimondiSara GastoldiMiriam GalbuseraRoberta DonadelliCaterina MeleRossella PirasMarina NorisValentina PortalupiLaura CappellettiCamillo CarraraFederica TomatisSilvia BernardiAnnalisa PernaTobia PeracchiOlimpia DiadeiAriela BenigniGuiseppe Remuzzi

Published in: PloS one (2021)

In patients with severe COVID-19, eculizumab safely improved respiratory dysfunction and decreased the combined endpoint of mortality and discharge with chronic complications. Findings need confirmation in randomised controlled trials.

Keyphrases

coronavirus disease
positive airway pressure
obstructive sleep apnea
sleep apnea
sars cov
respiratory syndrome coronavirus
early onset
risk factors
drug induced
oxidative stress
cardiovascular events
cardiovascular disease
intensive care unit
coronary artery disease
mechanical ventilation
respiratory tract